US Patent 10227325 Antiproliferative compounds, and their pharmaceutical compositions and uses
Patent 10227325 was granted and assigned to Celgene on March, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+160 characters)
Article
Patent abstract
Compounds of formula A-I and B-I, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
John Sapienza0
Joshua Hansen0
Matthew D. Alexander0
Matthew D. Correa0
Raj Kumar Raheja0
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102273250
Date of Patent
March 12, 2019
0Patent Application Number
159083660
Date Filed
February 28, 2018
0Patent Citations Received
Patent Primary Examiner
Edits on 22 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 2 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10227325 Antiproliferative compounds, and their pharmaceutical compositions and uses
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10227325
Date of patent
March 12, 2019
Patent application number
15908366
Date Filed
February 28, 2018
Patent primary examiner
Find more entities like US Patent 10227325 Antiproliferative compounds, and their pharmaceutical compositions and uses
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
